CombiGene
3,57 SEK -1,11%Vær den første som følger denne virksomhed
CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.
Omsætning
5,54 mio.
EBIT %
-696,75 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
COMBI
Daglig lav / høj pris
3,57 / 3,61
SEK
Markedsværdi
70,69 mio. SEK
Aktieomsætning
4,63 t SEK
Volumen
1,3 t
Finanskalender
Delårsrapport
17.05.2024
Generalforsamling
23.05.2024
Delårsrapport
23.08.2024
Delårsrapport
08.11.2024
Årsrapport
14.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Jan Ivar Nordqvist | 9,4 % | 9,4 % |
Pareto Securities | 5,6 % | 5,6 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
CombiGene’s epilepsy project CG01 has been granted patent in two new countries
BioStock: Comments from Orphazyme on the investment in CombiGene
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools